WCLC 2025 - Posters & ePosters-EP.12.65 Factors Impacting Targeted Therapy Use in Stage Iv Non-Small Cell Lung Cancer Patients With Infrequent Actionable Mutations

EP.12.65 Factors Impacting Targeted Therapy Use in Stage Iv Non-Small Cell Lung Cancer Patients With Infrequent Actionable Mutations

Back to course

Pdf Summary

This study evaluates factors influencing the use of targeted therapies in patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) harboring infrequent actionable mutations (ALK, ROS1, BRAF V600E, MET Exon 14 skipping, RET, or NTRK1/2/3) treated in U.S. oncology practices between 2022 and 2024. The cohort included 185 patients confirmed via chart abstraction, assessing demographic and clinical variables such as age, sex, race, ECOG performance status, histology, cancer stage, metastatic site, testing method, and test turnaround time (TAT) to determine their impact on receipt of targeted therapy.<br /><br />Results showed patients with adenocarcinoma histology were more likely to receive targeted treatments than those with squamous cell carcinoma. Similarly, patients with bone metastases had higher targeted therapy utilization compared to those with brain/CNS or liver metastases. Other factors, including sex, race, ECOG status, cancer sub-stage (IVA vs. IVB), testing method (liquid vs. solid biopsies), and TAT (time to receive molecular test results), did not have statistically significant impacts on targeted treatment use, although some differences in percentages were noted.<br /><br />For instance, females slightly more often received targeted therapy than males, and patients with better performance status (ECOG 0-1) tended to have higher targeted therapy rates; however, these did not reach statistical significance. The TAT was variable but not significantly associated with therapy receipt.<br /><br />In conclusion, this real-world analysis demonstrates that for stage IV NSCLC patients with rare actionable mutations, histology type and metastatic site influence targeted therapy administration, while other demographic and clinical factors do not show a significant effect. The study highlights a need for further investigation into barriers limiting targeted therapy use in patients with identified actionable mutations despite guideline recommendations.

Asset Subtitle

Mike Gart

Meta Tag

Speaker Mike Gart

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

stage IV NSCLC

targeted therapy

rare actionable mutations

ALK mutation

ROS1 mutation

BRAF V600E

MET Exon 14 skipping

RET mutation

NTRK1/2/3 mutations

metastatic site influence